-
3-Aminobenzamide: From PARP Biology to Translation
2026-09-12
A translational framework for using 3-Aminobenzamide (PARP-IN-1) to connect PARP-dependent stress biology with vascular, metabolic, and antiviral research while preserving mechanistic rigor, model-specific validation, and appropriate interpretation limits.
-
DAPI Workflows for Cancer Cell Fate Analysis
2026-09-12
DAPI converts nuclear integrity and chromatin morphology into practical readouts for fixed-cell imaging, viability screening, apoptosis-oriented analysis, and flow cytometry. This workflow connects those measurements to microbiome–breast cancer research while clearly separating what DAPI can reveal from what requires molecular or metabolic assays.
-
PBA-Modified PAD4 Inhibitors Block Tumor NETs
2026-09-11
The reference study developed phenylboronic acid-modified PAD4 inhibitors to improve tumor targeting and suppress the PAD4–H3cit–NET pathway. Compound 5i limited tumor growth and lung metastasis in mouse models primarily by acting on neutrophil biology rather than directly killing tumor cells, highlighting a targeted strategy for tumor-microenvironment intervention.
-
Intestinal TM6SF2 and the Gut–Liver Axis in MASH
2026-09-11
The reference study shows that intestinal TM6SF2 protects against metabolic dysfunction-associated steatohepatitis by preserving epithelial barrier function and constraining microbiota- and lipid-mediated signaling. Genetic, microbiota-transfer, and pharmacological experiments connect intestinal TM6SF2 loss to pathobiont enrichment, elevated lysophosphatidic acid, hepatic lipid accumulation, and inflammation.
-
Simvastatin (Zocor) for Translational Cell Assays
2026-09-10
Simvastatin (Zocor) connects cholesterol-biosynthesis studies with apoptosis, cell-cycle, and high-content phenotyping workflows. This bench-focused guide shows how to manage its prodrug biology, solvent limitations, dose selection, and cross-cell-line assay transfer.
-
Of Chloroquine and COVID-19: Evidence and Limits
2026-09-10
Touret and de Lamballerie’s commentary placed early enthusiasm for chloroquine against the broader antiviral literature, showing that cell-culture activity has repeatedly failed to predict clinical benefit. Its central contribution is a translational warning: antiviral effects must be evaluated across animal models, human trials, immune consequences, and safety constraints rather than inferred from in vitro results alone.
-
Nanocarrier-Mediated dsRNA Transdermal Delivery
2026-09-09
Guan and colleagues investigate how a star cationic polymer enables double-stranded RNA to cross the insect cuticle, identifying wax-layer dissolution and reduced chitin-layer resistance as complementary mechanisms. The study provides a mechanistic framework for designing noninvasive RNAi delivery systems while clarifying why cuticle structure, wetting, and carrier–barrier interactions must be considered together.
-
Genotyping Kit for target alleles: PCR-Ready DNA
2026-09-09
Convert insect, fish, tissue, and cell samples into PCR-ready genomic DNA without phenol extraction, spin columns, or overnight processing. APExBIO’s K1026 combines single-tube lysis with a dye-containing 2× PCR Master Mix for practical allele screening and model validation.
-
Sabutoclax: A Pan-Bcl-2 Inhibitor for Apoptosis
2026-09-08
Sabutoclax supports apoptosis-focused studies that distinguish genuine cell killing from simple growth suppression. This guide connects target-level potency, paired viability and death assays, cancer-cell models, and troubleshooting strategies for more interpretable results.
-
Puerarin Activates NO Signaling in Dental Follicle Cells
2026-09-08
The reference study shows that puerarin promotes osteogenic differentiation of rat dental follicle cells while increasing nitric oxide, cGMP, and osteogenic markers. Pharmacological inhibition with L-NMMA reversed these effects, supporting a functional role for nitric oxide pathway modulation in periodontal regeneration research.
-
Paclitaxel (Taxol): From Assay to Nanotherapy
2026-09-07
Paclitaxel (Taxol) is more than a mitotic inhibitor: it is a powerful experimental benchmark for connecting microtubule biology with targeted drug delivery. This article explains how carrier-free paclitaxel formulations reshape assay design, controls, and interpretation in cancer research.
-
FPH1 (BRD-6125) Hepatocyte Workflows
2026-09-05
FPH1 (BRD-6125) supports a practical route to expand hepatocyte populations while preserving functionally relevant readouts such as albumin secretion and CYP3A4. This guide connects primary human hepatocyte culture and iPSC-derived hepatocyte workflows with assay design, troubleshooting, and a carefully bounded perspective on light-regulated gene therapy.
-
PD0325901: MEK Inhibition in Chromatin Assays
2026-09-05
PD0325901 combines a clear pharmacodynamic readout—reduced phosphorylated ERK—with phenotypic endpoints such as G1/S arrest and apoptosis. This guide shows how to use the MEK inhibitor in cancer models and pair pathway perturbation with single-molecule chromatin assays inspired by recent nucleosome research.
-
Isoproterenol Sulfate Dihydrate in SAN Assays
2026-09-04
Learn how to use Isoproterenol sulfate dihydrate as a controlled beta-adrenergic challenge in human SAN, cardiac plexus, and atrial assembloid experiments. The workflow separates direct pacemaker-cell responses from neural modulation while improving dose control, formulation consistency, and troubleshooting.
-
Cy3 Goat Anti-Human IgG (H+L): From Signal to Meaning
2026-09-04
The Cy3 Goat Anti-Human IgG (H+L) Antibody supports sensitive fluorescence detection across immunoassays. This article explains how to connect secondary-antibody signal with epitope-aware interpretation, using orthopoxvirus antibody research to define practical assay boundaries.